Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Share-based Compensation (2023 - 2025)

Bioharvest Sciences has reported Share-based Compensation over the past 3 years, most recently at $148000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 0.68% year-over-year to $148000.0; the TTM value through Dec 2025 reached $597000.0, down 0.67%, while the annual FY2025 figure was $597000.0, 0.67% down from the prior year.
  • Share-based Compensation was $148000.0 for Q4 2025 at Bioharvest Sciences, up from $133000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $195000.0 in Q2 2024 and bottomed at $118000.0 in Q3 2023.
  • The 3-year median for Share-based Compensation is $133000.0 (2024), against an average of $144800.0.
  • Year-over-year, Share-based Compensation grew 11.36% in 2024 and then decreased 5.64% in 2025.
  • Over 3 years, Share-based Compensation stood at $132000.0 in 2023, then increased by 11.36% to $147000.0 in 2024, then rose by 0.68% to $148000.0 in 2025.
  • The last three reported values for Share-based Compensation were $148000.0 (Q4 2025), $133000.0 (Q3 2025), and $184000.0 (Q2 2025) per Business Quant data.